In the BioHarmony Drug Report Database
Naxitamab
Danyelza (naxitamab) is an antibody pharmaceutical. Naxitamab was first approved as Danyelza on 2020-11-25. It is used to treat neuroblastoma in the USA.
Trade Name
|
Danyelza |
|---|---|
Common Name
|
naxitamab |
ChEMBL ID
|
CHEMBL4297984 |
Indication
|
neuroblastoma |
Drug Class
|
Monoclonal antibodies: tumors |
Image (chem structure or protein)
